Developmental Therapeutics Research Program

发育治疗研究计划

• 批准号: 8558287
• 负责人: Thomas James Lynch
• 金额: $ 2.12万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8558287
• 关键词: Adverse effects; Am 80; Antibodies; Antineoplastic Agents; Antiviral Agents; Area; Basic Science; Biochemical; Biological; Biological Factors; Biological Markers; Biological Products; Biological Response Modifiers; Botanicals; Cancer Center Support Grant; Cell Cycle; Cell Proliferation; Chemistry; Chemotherapy-Oncologic Procedure; Chinese Herbs; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Conduct Clinical Trials; Cytotoxic Chemotherapy; DNA biosynthesis; Development; Developmental Therapeutics Program; Direct Costs; Doctor of Philosophy; Drug Design; Drug Industry; Drug resistance; Enzymes; Extramural Activities; Fostering; Funding; Funding Opportunities; Future; Gene Mutation; Genetic; Goals; Grant; HIV; Health; Human; Instruction; Lead; Leadership; Licensing; Malignant Neoplasms; Medicine; Metabolic Pathway; Mission; Modality; Molecular; Molecular Profiling; Molecular Target; Molecular Virology; Neoplasm Metastasis; Outcome; Paper; Peer Review; Peptides; Pharmaceutical Preparations; Pharmacodynamics; Phase; Population; Preclinical Drug Evaluation; Preclinical Testing; Prevention; Publishing; Recruitment Activity; Research; Research Personnel; Role; Satellite Viruses; Science; Scientific Advances and Accomplishments; Scientist; Signal Transduction; Signal Transduction Pathway; Structure; Techniques; Therapeutic; Therapeutic Human Experimentation; Therapy Clinical Trials; Tissues; Translating; Translational Research; Translations; Viral; Virus; Virus Diseases; Work; Yale Cancer Center; angiogenesis; base; cancer cell; cancer therapy; cancer type; cell growth; chemotherapy; design; drug development; drug discovery; innovation; interest; meetings; member; molecular pathology; novel; novel therapeutic intervention; novel therapeutics; patient population; peptidomimetics; pre-clinical; preclinical study; prognostic; programs; research clinical testing; success; translational medicine; treatment strategy; tumor; working group

PROJECT SUMMARY (See instructions): The Developmental Therapeutics (DT) Research Program is a long-standing research program, established in 1974 as the first research program of the Yale Cancer Center (YCC). This program has 48 members representing 15 departments. The DT program has three main program goals: 1. To identify and characterize key molecular targets and therapeutic strategies for treatment of cancer and cancer-associated viral disease; 2. To foster and facilitate interactions between basic and clinical investigators interested in drug development; and 3. To translate YCC discoveries and science into the clinic using clinical trials which explore prognostic, predictive and pharmacodynamic biomarkers. This program has been highly successful in developing therapeutics as illustrated by considering a snapshot of recent scientific accomplishments. In work initiated during the previous grant period, twenty-five molecules have been discovered by DT members; 18 have been licensed to the pharmaceutical industry; 9 are undergoing preclinical testing; and 6 anticancer agents are in clinical testing in Phase I, II, and III trials. This includes carfilzomib that received FDA approval in July 2012 that was developed in the lab of Craig Crews in the previous grant period. The new leaders of the DT Program are Karen S. Anderson, PhD and Roy S. Herbst, MD, PhD, with basic science and clinical/translational expertise in structure-based drug design/drug discovery and translational research, personalized cancer therapies, and clinical trials. Dr. Anderson's primary role is to foster basic science clinical partnerships and facilitate the translation of basic science discoveries to preclinical studies. Dr. Herbst's role is to promote translational and clinical programs. This includes building multi-investigator teams comprised of basic, clinical, and population scientists assembled as tumor-type working groups that are focused on the various types of cancer. In addition, we recruited Dr. Paul Eder to lead the Phase I, DT effort. Under this new leadership, more molecules will enter trials at Yale in the future. The cancer-focused research of DT members has significantly benefited from YCC pilot grant funding. Since the last submission, $855,727 in YCC pilot funds have yielded over $8.4 million in extramural funding including 1 ROI and 1 P01 as well as 2 clinical trials. The funding in the DT program is quite robust with a total cancer-related funding of $16,693,963. Of this, over 80% is peer-reviewed ($13,233,968) and $4,240,718 ($2.8 direct costs) is from NCI. During the previous grant period (2006-11), members of this program published 397 cancer-related papers. This includes 179 that were collaborative, of which 42% were inter-programmatic and 9% were intraprogrammatic.

项目总结(见说明)： 发展治疗(DT)研究计划是一个长期的研究计划，成立于1974年，是耶鲁大学癌症中心(YCC)的第一个研究计划。这个项目有代表15个部门的48名成员。DT计划有三个主要计划目标：1.确定和表征治疗癌症和癌症相关病毒疾病的关键分子靶点和治疗策略；2.促进和促进对药物开发感兴趣的基础和临床研究人员之间的互动；3.利用探索预后、预测和药效学生物标志物的临床试验，将YCC的发现和科学转化为临床。这个项目在开发治疗学方面非常成功，正如考虑到最近的科学成就的快照所示。在前一批赠款期间启动的工作中，DT成员发现了25个分子；18个已被批准用于制药业；9个正在进行临床前试验；6个抗癌药物正在进行第一、第二和第三阶段的临床试验。这包括2012年7月获得FDA批准的carfilzomib，它是在上一次授权期内由Craig Crews的实验室开发的。DT计划的新领导者是Karen S.Anderson博士和Roy S.Herbst博士，他们在基于结构的药物设计/药物发现和翻译研究、个性化癌症治疗和临床试验方面拥有基础科学和临床/翻译专业知识。安德森博士的主要职责是促进基础科学临床伙伴关系，并促进将基础科学发现转化为临床前研究。赫布斯特博士的角色是促进翻译和临床项目。这包括建立由基础、临床和人口科学家组成的多研究团队，作为肿瘤类型的工作组，专注于各种类型的癌症。此外，我们聘请了Paul Eder博士来领导第一阶段的DT工作。在这一新领导层的领导下，未来将有更多的分子进入耶鲁大学的试验。DT成员以癌症为重点的研究大大受益于YCC试点拨款。自上次提交以来，855,727美元的YCC试点资金已产生超过840万美元的外部资金，包括1个ROI和1个P01以及2个临床试验。DT计划的资金相当强劲，与癌症相关的资金总额为16,693,963美元。其中，80%以上是同行评审(13,233,968美元)，4,240,718美元(2.8美元直接成本)来自NCI。在之前的资助期间(2006-11)，该计划的成员发表了397篇与癌症有关的论文。这包括179个协作性方案，其中42%是方案间方案，9%是方案内方案。